© 2022 MJH Life Sciences and Managed Healthcare Executive. All rights reserved.
© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
A multi-stakeholder panel discussion featuring insight on the use of prescription digital therapeutics as tools when managing behavior-driven conditions.
January 6th 2021
Clinicians, a pharmacist, and a payer discuss their current experience with prescription digital therapeutics for behavior-driven conditions and share considerations for expanding on their use in clinical practice.
Nidal Moukaddam, MD, PhD, Baylor College of Medicine, comments on where she sees prescription digital therapeutics being most useful when managing behavior-driven conditions.
Payer and provider insight regarding the potential impact prescription digital therapeutics could have on addressing challenges surrounding the management of behavior-driven conditions.
Current experiences noted by various stakeholders in healthcare regarding the impact of prescription digital therapeutics in clinical practice as tools to help manage patients with behavior-driven conditions, and current limitations that need to be addressed to increase their uptake.
Considerations regarding opportunities to increase payer and provider uptake of prescription digital therapeutics into clinical practice to optimize care for patients with behavior-driven conditions.
Steven Peskin, MD, MBA, FACP, shares perspective on factors that need to be considered by payers when making decisions about how to cover and reimburse for prescription digital therapeutics used to manage behavior-driven conditions.
Healthcare providers comment on what clinicians would like to see, in terms of data and education, that would help justify the prescribing of digital therapeutics for behavior-driven conditions.
Considerations regarding the impact of COVID-19 on managing patients with behavior-driven conditions, and its positive effects on increasing attention around the topic of prescription digital therapeutics.